Cogent Biosciences (COGT) files mixed shelf
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Wall St set for mixed open ahead of SK Hynix listing; Middle East in focus
- Oil heads for weekly gains as Middle East supply risks persist
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
Cogent (COGT) PT Raised to $50 at Leerink Partners
November 10, 2025 1:18 PM ESTLeerink Partners analyst Andrew Berens raised the price target on Cogent (NASDAQ: COGT) to $50.00 (from $18.00) while maintaining a Outperform rating.
The analyst comments "This morning, COGT announced topline results for the Ph 3 PEAK trial and hosted a conference call. As a reminder, PEAK evaluated the KIT inhibitor bezuclastinib (bezu) in combination with sunitinib vs sunitinib monotherapy in patients with gastrointerstinal stromal tumors (GIST) after progression on the 1L therapy imatinib. We view the results obtained in the 2L as offering unprecedented efficacy... More
Stifel Upgrades Cogent (COGT) to Buy
November 10, 2025 10:54 AM ESTStifel analyst Laura Prendergast upgraded Cogent (NASDAQ: COGT) from Hold to Buy with a price target of $40.00 (from $16.00).
The analyst comments "Today, COGT reported overwhelmingly positive results in the Ph3 PEAK study of bezuclastinib plus sunitinib vs. sunitinib alone in 2L GIST... More
